339 related articles for article (PubMed ID: 19250681)
1. Structural characterization of a human Fc fragment engineered for extended serum half-life.
Oganesyan V; Damschroder MM; Woods RM; Cook KE; Wu H; Dall'acqua WF
Mol Immunol; 2009 May; 46(8-9):1750-5. PubMed ID: 19250681
[TBL] [Abstract][Full Text] [Related]
2. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
[TBL] [Abstract][Full Text] [Related]
3. Structural characterization of a mutated, ADCC-enhanced human Fc fragment.
Oganesyan V; Damschroder MM; Leach W; Wu H; Dall'Acqua WF
Mol Immunol; 2008 Apr; 45(7):1872-82. PubMed ID: 18078997
[TBL] [Abstract][Full Text] [Related]
4. Quantitative methods for developing Fc mutants with extended half-lives.
Kamei DT; Lao BJ; Ricci MS; Deshpande R; Xu H; Tidor B; Lauffenburger DA
Biotechnol Bioeng; 2005 Dec; 92(6):748-60. PubMed ID: 16136591
[TBL] [Abstract][Full Text] [Related]
5. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).
Dall'Acqua WF; Kiener PA; Wu H
J Biol Chem; 2006 Aug; 281(33):23514-24. PubMed ID: 16793771
[TBL] [Abstract][Full Text] [Related]
6. Crystal structure of the complex of rat neonatal Fc receptor with Fc.
Burmeister WP; Huber AH; Bjorkman PJ
Nature; 1994 Nov; 372(6504):379-83. PubMed ID: 7969498
[TBL] [Abstract][Full Text] [Related]
7. An "Fc-Silenced" IgG1 Format With Extended Half-Life Designed for Improved Stability.
Borrok MJ; Mody N; Lu X; Kuhn ML; Wu H; Dall'Acqua WF; Tsui P
J Pharm Sci; 2017 Apr; 106(4):1008-1017. PubMed ID: 28057542
[TBL] [Abstract][Full Text] [Related]
8. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure at 2.2 A resolution of the MHC-related neonatal Fc receptor.
Burmeister WP; Gastinel LN; Simister NE; Blum ML; Bjorkman PJ
Nature; 1994 Nov; 372(6504):336-43. PubMed ID: 7969491
[TBL] [Abstract][Full Text] [Related]
10. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
Wang Y; Tian Z; Thirumalai D; Zhang X
J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
[TBL] [Abstract][Full Text] [Related]
11. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates.
Yeung YA; Leabman MK; Marvin JS; Qiu J; Adams CW; Lien S; Starovasnik MA; Lowman HB
J Immunol; 2009 Jun; 182(12):7663-71. PubMed ID: 19494290
[TBL] [Abstract][Full Text] [Related]
12. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
13. Computational determination of the structure of rat Fc bound to the neonatal Fc receptor.
Weng Z; Gulukota K; Vaughn DE; Bjorkman PJ; DeLisi C
J Mol Biol; 1998 Sep; 282(2):217-25. PubMed ID: 9735282
[TBL] [Abstract][Full Text] [Related]
14. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies.
Wang W; Vlasak J; Li Y; Pristatsky P; Fang Y; Pittman T; Roman J; Wang Y; Prueksaritanont T; Ionescu R
Mol Immunol; 2011 Mar; 48(6-7):860-6. PubMed ID: 21256596
[TBL] [Abstract][Full Text] [Related]
15. Reduced elimination of IgG antibodies by engineering the variable region.
Igawa T; Tsunoda H; Tachibana T; Maeda A; Mimoto F; Moriyama C; Nanami M; Sekimori Y; Nabuchi Y; Aso Y; Hattori K
Protein Eng Des Sel; 2010 May; 23(5):385-92. PubMed ID: 20159773
[TBL] [Abstract][Full Text] [Related]
16. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies.
Davis JH; Aperlo C; Li Y; Kurosawa E; Lan Y; Lo KM; Huston JS
Protein Eng Des Sel; 2010 Apr; 23(4):195-202. PubMed ID: 20299542
[TBL] [Abstract][Full Text] [Related]
17. Fc engineering: serum half-life modulation through FcRn binding.
Olafsen T
Methods Mol Biol; 2012; 907():537-56. PubMed ID: 22907373
[TBL] [Abstract][Full Text] [Related]
18. Conformational Destabilization of Immunoglobulin G Increases the Low pH Binding Affinity with the Neonatal Fc Receptor.
Walters BT; Jensen PF; Larraillet V; Lin K; Patapoff T; Schlothauer T; Rand KD; Zhang J
J Biol Chem; 2016 Jan; 291(4):1817-1825. PubMed ID: 26627822
[TBL] [Abstract][Full Text] [Related]
19. Binding of divalent H-2Kd/IgG2aFc fusion protein to murine macrophage via Fc-FcR interaction.
Xiao W; Chen X; Lin Zhou ; Lu S; Liang Z; Wu X
Cell Mol Immunol; 2007 Apr; 4(2):147-51. PubMed ID: 17571461
[TBL] [Abstract][Full Text] [Related]
20. Identification of critical IgG binding epitopes on the neonatal Fc receptor.
Vaughn DE; Milburn CM; Penny DM; Martin WL; Johnson JL; Bjorkman PJ
J Mol Biol; 1997 Dec; 274(4):597-607. PubMed ID: 9417938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
